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Abstract
Background: Enrolling participants in clinical trials can be challenging, especially with respect to prophylactic vaccine
trials. The vaccination of study personnel in Ebola vaccine trials during the 2014–2016 epidemic played a crucial role in
inspiring trust and facilitating volunteer enrollment. We evaluated the ethical and methodological considerations as
they applied to an ongoing phase 2 randomized prophylactic Ebola vaccine trial that enrolled healthy volunteers in
Guinea, Liberia, Sierra Leone, and Mali in a non-epidemic context.
Methods: On the assumption that the personnel on site involved in executing the protocol, as well as community
mobilizers (not involved in the on-site procedures), might also volunteer to enter the trial, we considered both ethical
and methodological considerations to set clear rules that can be shared a priori with these persons. We reviewed the
scientific and gray literature to identify relevant references and then conducted an analysis of the ethical and
methodological considerations.
Results: There are currently no regulations preventing a clinical investigator or site staff from participating in a
trial. However, the enrollment of personnel raises the risk of undue influence and challenges the basic ethical
principle of voluntary participation. The confidentiality of personal medical information, such as HIV test results,
may also be difficult to ensure among personnel. There is a risk of disruption of trial operations due to the
potential absence of the personnel for their commitment as trial participants, and there is also a potential for
introducing differential behavior of on-site staff as they obtain access to accumulating information during the
trial (e.g., the incidence of adverse events). Blinding could be jeopardized, given knowledge of product-specific
adverse event profiles and the proximity to unblinded site staff. These aspects were considered more relevant for
on-site staff than for community mobilizers, who have limited contact with site staff.
Conclusion: In a non-epidemic context, ethical and methodological considerations limit the collective benefit of
enrolling site staff in a vaccine trial. These considerations do not apply to community mobilizers, whose potential
enrollment should be considered as long as they meet the inclusion criteria and they are not exposed to any
form of coercion.
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Introduction
The 2014–2016 Ebola virus disease outbreak in Guinea,
Liberia, and Sierra Leone included more than 28,000 cases
and more than 11,000 deaths [1]. The scale of the outbreak
was unprecedented and prompted the development of
prophylactic vaccine candidates [2–4]. A number of clinical
vaccine trials were conducted in the affected countries
during the epidemic [4–7]. Although these studies made
many advances during the epidemic, further research is
required to prevent and limit the impact of further out-
breaks, such as the current outbreak in the Democratic
Republic of the Congo [8]. Therefore, Ebola vaccine clinical
trials continue to be conducted in a non-epidemic context.
Recruiting and enrolling participants in any clinical trial
can be challenging, but this is especially true in the case of
prophylactic vaccine trials; participants are volunteers
from the community and do not have the specific disease,
but rather are at hypothetical risk thereof. The Ebola
epidemic context bred a well-documented climate of fear
and mistrust [9, 10]. Therefore, setting up vaccine trials
during the epidemic required the development of unique,
highly sensitive communication (community engagement)
strategies, specific to the socio-cultural context, to engage
local populations in interventional research and thus
facilitate study enrollment. One of the strategies used
to inspire trust and combat rumors was the enroll-
ment of “study staff,” i.e., local healthcare pro-
fessionals working at the study site, as exemplified by
the PREVAIL 1 trial in Liberia [5]. Nevertheless, in a
non-epidemic context where there is no indication for
emergency vaccination with vaccine candidates still being
under development, the enrollment of study staff raises
ethical and methodological concerns.
These considerations have been examined while setting
up the Partnership for Research on Ebola Vaccinations
(PREVAC) trial, a randomized phase 2 double-blind vac-
cine trial evaluating the immunogenicity and the safety of
three prophylactic vaccine strategies against Ebola
(NCT02876328). In this trial, healthy adult and children
(aged ≥1 year) volunteers have been enrolled in Guinea
and Liberia since March 2017, and in Sierra Leone and
Mali, since respectively May and July 2018; the trial is
ongoing. For this prophylactic vaccine clinical trial con-
ducted in West Africa, study personnel of the PREVAC
trial comprise the clinical study site staff and the commu-
nity mobilizers, both employed and paid by the trial
sponsors or their delegates. The clinical study site staff
comprises the medical team, nurses, pharmacists, lab
technicians, administrative personnel, logistics personnel,
and communications staff. The community mobilizers are
involved in recruitment and follow-up of participants
within the communities. In the case of PREVAC, they
were recruited based on a profile of community workers
and community champions. Figures of exemplarity within
their communities (e.g., football/soccer coach, nurse) were
encouraged to apply for these positions because of their
strong community involvement.
In this article, we examined the ethical and methodo-
logical considerations of enrolling study personnel in
Ebola vaccine trials in a non-epidemic context. We then
defined the most appropriate course of action for the
implementation of the PREVAC trial in Guinea.
Methods
We performed a review of the scientific literature using
the PubMed electronic database, and of the gray litera-
ture [11] using Google searches for documents pub-
lished on the Internet (in English and French), to
identify relevant references regarding the enrollment of
study personnel in clinical trials. Key words used for the
literature search were “enrollment”, “study personnel”,
“staff”, and “clinical trials”. For the review of the scien-
tific literature, the selection was performed on the title
and abstract, and then in a second step by reading the
full article. For the gray literature, as it is impossible to
screen all retrieved results from Google searches, we
screened the most relevant results based on the Google
relevancy ranking on the first 15 pages. The search was
performed on March 2017 with a publication date limit
of the same date. We then examined the methodological
and ethical considerations pertaining enrolling study
personnel in a prophylactic Ebola vaccine trial outside of
an epidemic context.
As community mobilizers are rarely present at the
vaccination sites (mainly being present only to provide
information for the purposes of the participant consent
process) and are not involved in the vaccination process,
we assumed that some of the ethical and methodological
considerations would not apply to them. Therefore, we
distinguished between the two types of personnel—clin-
ical study site staff and community mobilizers—for the
evaluation of ethical and methodological considerations.
We then reached a consensus on how to proceed in
the context of PREVAC in Guinea in March 2017 after
studying all the ethical and methodological consider-
ations. This decision was made in a multidisciplinary
fashion involving the sponsor, the investigator coordin-
ator of the study, the clinical trial unit responsible for
the trial methodology, anthropologists, and study staff in
the field.
Results
Assessment of the ethical and methodological
considerations
We found no regulations preventing a clinical investigator
or site staff from participating in a trial. No relevant bio-
medical literature was identified in PubMed among 325
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articles retrieved. Our main sources were thus reference
sources pertaining to the protection of human subjects
such as the Declaration of Helsinki and the Belmont
Report [12, 13], International Ethical Guidelines for
Biomedical Research Involving Human Subjects [14],
and the Institutional Review Board Guidebook of the
Office for Human Research Protections (USA), espe-
cially Chapter 6 which concerns special classes of
subjects [15].
The ethical and methodological features and challenges
associated with enrolling study personnel in a prophylactic
Ebola vaccine trial are summarized in Table 1.
Respect for persons is a fundamental principle of me-
dical research involving human subjects. As defined in
the Belmont Report [13], respect for persons incorpo-
rates that individuals should be treated as autonomous
agents and requires that subjects, to the degree that they
are capable, be given the opportunity to choose what
Table 1 Ethical and methodological considerations according to the type of study personnel to be potentially included in a
prophylactic Ebola vaccine clinical trial conducted in West Africa outside of the context of an active epidemic
Principles Considerations Explanation Affected study personnel
Clinical study
site staff
Community
mobilizers
Ethical principles
Respect for persons: no
research without informed
consent of those involved,
respect of autonomy, the
requirement to protect
those with diminished
autonomy
Direct or indirect undue
influence regarding
participation in the trial
As with other participants in a clinical trial,
the participation of study staff must always
be voluntary
Yes Yes
Beneficence: do not harm
and maximize possible
benefits and minimize
possible harms
No particular consideration:
the risks and benefits of the
research are the same for all
the participants
Justice: respect for the
principle of equality of human beings,
fair treatment during
investigations
Breach of confidentiality
regarding medical information
Every precaution must be taken to protect
the privacy of research subjects and the
confidentiality of their personal information
Yes No
Methodological principles
Subject selection Eligibility criteria As with other participants, any study staff
enrolled must meet the eligibility criteria and
participate in the information session, and
give informed consent
Yes Yes
Selection of an adequate
control group
No particular consideration
Number of subjects:
statistical assessments of
sample size
No particular consideration
Response variables: primary
and secondary endpoints
No particular consideration
Methods to minimize or
assess bias: randomization,
blinding, compliance
Imperfect blinding Maintaining blinding could be difficult due to
the proximity to unblinded site personnel
and potential knowledge of product-specific
adverse events
Yes No
Dropout rate differences
between arms
The study staff enrolled as participants may
have access to accumulating information
during the trial to which other participants
do not typically have access (e.g., overall
adverse event rates)
Yes No
Analysis: the study protocol
should have a specified
analysis plan that is
appropriate for the
objectives and design of the study
No particular consideration
Other Disruption of trial operations During their participation in trial activities as
participants, the staff are not available to
perform their professional duties
Yes Yes
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shall or shall not happen to them. This opportunity is
provided when adequate standards for informed consent
are satisfied. Participation must always be voluntary, and
the volunteer has the right to refuse to participate in a
study or to withdraw consent to participate at any time.
Regarding this point, our consideration concerns the risk
of direct or indirect undue influence because staff may
feel pressured to join the clinical trial due to the
hierarchical relationship with the employer. This consi-
deration concerns clinical study site staff as well as
community mobilizers, who are both in a dependent re-
lationship with the employer.
The second ethical consideration is related to the
principle of justice (i.e., respect of the principle of equality
of human beings, fair treatment during investigations),
where there is a risk of a breach of confidentiality of
medical information. For example, confidentiality could
be difficult to ensure in the case that a colleague has to
inform a participant about a positive human immuno-
deficiency virus (HIV) test result. This concern, however,
applies only to clinical study site staff, as community
mobilizers do not work directly with other study staff.
Regarding the ethical principle of beneficence (i.e., do
not harm and maximize possible benefits and minimize
possible harms), no particular consideration was raised
for the staff, as the risks and benefits of the research are
the same for all the participants.
Regarding the methodological aspects, we identified
three different points to consider. The first one is a
logistical risk of disruption of trial operations due to the
potential absence of the personnel for their commitment
to trial activities as participants. As participants, all
included personnel must adhere to the same trial pro-
cedures and follow-up as the other participants. This
affects both clinical study site staff and community
mobilizers, as it requires their availability as participants
during working hours and conflicts with their pro-
fessional duties as trial staff.
One of the methods used to minimize bias in clinical
trials is blinding, which allows maintaining the same
follow-up procedures and measurement of endpoints in
the different randomized groups. The second methodo-
logical risk we identified concerns imperfect blinding in
the case of single- or double-blind clinical trials, due to
the potential knowledge of product-specific adverse
events and to the proximity to unblinded site personnel.
Vaccines are prepared on site in the pharmacy by
unblinded personnel, and complete blinding is often
impossible due to differences in color or viscosity
between the active vaccine and placebo, even when
using opaque syringes. Despite all precautions taken to
achieve blinding, site staff are often familiar with subtle
differences between the tested interventions that are not
apparent to the participants.
The third methodological point concerns the risk of
non-differential dropout rates, as the study staff enrolled
as participants may have access to accumulating in-
formation during the trial to which other participants do
not typically have access. For example, staff may be
aware of the overall incidence of adverse events in the
trial and are more likely to discontinue their participa-
tion in the trial on that basis. If blinding is maintained,
this can lead to non-differential dropout rates between
arms and therefore a loss of information and power. In
the case of imperfect blinding, these dropout rates can
be differential. These last two concerns do not apply to
community mobilizers, who have a more distant rela-
tionship with the study site, are not involved in on-site
procedures, and lack access to accumulating confidential
information during the trial.
Regarding selection of subjects (eligibility criteria),
which is an important aspect of a clinical trial, study
staff enrolled must meet eligibility criteria, go through
an information session, and give informed consent, just
as the other participants do.
Definition of the appropriate course of action for
implementing the PREVAC trial in Guinea
Given the ethical and methodological concerns we
have described, the study team in Guinea decided not
to enroll investigators or site staff as participants in
the trial. As community mobilizers are prominent
figures who are trusted within the community, and
given that most of the methodological and ethical
factors did not apply to them, we allowed their
enrollment in the trial under the following conditions:
First, participation had to be voluntary and not re-
lated to the terms of employment. This fundamental
principle had to always be well explained to the
potential participants before consent was obtained;
this was mandatory. Second, like all other partici-
pants, they had to meet the eligibility criteria and
attend an information session, provide consent, and
enroll in the participant tracking process. Finally, all
site staff were reminded about their professional com-
mitment to secrecy, especially pertaining to the con-
fidentiality of medical information.
In October 2018, when the inclusion of participant in
the PREVAC trial in Guinea ended, a total of 10 commu-
nity mobilizers had been included in the trial, represent-
ing 13% of all community mobilizers working at
Guinean sites.
Discussion
The enrollment of study staff threatens two of the fun-
damental ethical principles of medical research involving
human subjects: voluntary participation and privacy/con-
fidentiality. It also raises logistical and methodological
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concerns that could jeopardize trial operations and blind-
ing and result in increased dropout rates.
Our literature review has highlighted a lack of specific
references regarding the participation of study staff to a
trial, in both the scientific literature and the regulatory
documents. Nevertheless, our review of scientific literature
was limited to the PubMed database. There is currently
no regulatory prohibition banning a clinical investigator or
site staff from participating in a trial. Indeed, it would be
difficult to draw up a general rule with regards to this. The
public health but also socio-cultural context must be con-
sidered when determining the course of action that should
be taken during the implementation of a clinical trial, es-
pecially in low-income settings and in emergency situa-
tions [8]. Regulatory authorities should consider making
general or specific recommendations according to the
study context, particularly in the case of a community trial
for which the staff may meet the eligibility criteria. In the
absence of specific rules, this matter should be addressed
by the sponsor, and the opinion of an ethics committee on
this question could also be sought before beginning the
trial. Several strategies can be deployed to strengthen the
protection of employees and minimize bias in this context
[16]: Measures that will be implemented to protect the
rights of employee participants should be described before
the implementation and be reviewed by an ethics commit-
tee; supervisors should not directly recruit subordinates
for research participation, or an independent party could
monitor the informed consent process.
Building trust in the communities in West Africa as
well as in other regions of the world is an essential step
for the successful implementation of any community
trial, including vaccine trials. The community engage-
ment strategies developed and successfully implemented
in previous vaccine trials in the epidemic Ebola context
supported the tremendous effort to rapidly conduct
much-needed health research on prophylactic vaccine
candidates. In the epidemic context, the enrollment of
study staff probably contributed to mobilize the commu-
nities, but this alone may not justify the implementation
of such an initiative. During an epidemic, vaccination
can potentially prevent the spread of a disease with high
incidence and lethality, and a major benefit of vaccina-
ting study staff could exist, provided that candidate vac-
cines have a risk-benefit ratio that has been sufficiently
evaluated and that the study is well designed. These
considerations could also apply to other emergent
infectious diseases with high incidence and lethality
and without effective prevention measures or available
therapeutic treatments.
Conclusion
The enrollment of study personnel can play a key role in
facilitating the enrollment of participants in a community
trial and may provide potential personal benefits, espe-
cially in an epidemic context where the risk-benefit ratio
is likely to be different from the non-epidemic one. In a
non-epidemic context, methodological and ethical con-
siderations suggest the need for increased caution. We
conclude that study personnel not involved in on-site
procedures and who meet the eligibility criteria without
risk of coercion can be considered for enrollment as
participants. Our structured analysis provides a framework
for the systematic examination of the specific pros
and cons during the preparation and implementation
of prophylactic vaccine trials.
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